3502 related articles for article (PubMed ID: 7378986)
1. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Costanzi JJ; Al-Sarraf M; Groppe C; Bottomley R; Fabian C; Neidhart J; Dixon D
Med Pediatr Oncol; 1982; 10(3):251-8. PubMed ID: 7045615
[TBL] [Abstract][Full Text] [Related]
4. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
[TBL] [Abstract][Full Text] [Related]
5. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
Robidoux A; Gutterman JU; Bodey GP; Hersh EM
Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
[TBL] [Abstract][Full Text] [Related]
6. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb perfusion for stage I melanoma of the extremity: a comparison of melphalan and dacarbazine (DTIC).
Edwards MJ; Boddie AW; Ames FC; McBride CM
South Med J; 1989 Aug; 82(8):985-7, 989. PubMed ID: 2762904
[TBL] [Abstract][Full Text] [Related]
8. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
10. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
Green MD; MacKay IR; Buckley JC; Coates AS
Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
Byrne MJ; Reynolds PM
Aust N Z J Med; 1982 Aug; 12(4):263-6. PubMed ID: 6958237
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Abdi EA; Hanson J; McPherson TA
Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
[TBL] [Abstract][Full Text] [Related]
14. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
15. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Smalley RV; Vogler WR
Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.
Karakousis CP; Emrich LJ
J Surg Oncol; 1987 Dec; 36(4):235-8. PubMed ID: 3695527
[TBL] [Abstract][Full Text] [Related]
19. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
20. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]